For next month I will go over the CTAD data in detail. Please, subscribed. I will post at least 3 post a week.
This Blog Is Only For Educational Purposes. Do Not Trade On This Blog Alone. Do Your Due Deligence or Consult Professional.
Subscribe to get access
Read more of this content when you subscribe today.
I downloaded copy of the paper listed on the slide 8 and that is what I learned.
Subscribe to get access
Read more of this content when you subscribe today.
Subscribe to get access
Read more of this content when you subscribe today.
Subscribe to get access
Read more of this content when you subscribe today.
Blarcamesine has the making of a drug which can become the first choise for patients with Parkinson’s, either slowing progress of the disease or even reversing it for some. The prospects here are even beter than they are with Alzheimer’s
I am sorry for multiple log-in buttons, I am learning how to use the editor, but the same login should be used for all paragraphs. I apologize.
